Chemotactic effect of joint effusions

B. STOJAN, J. F. BOREL, AND G. LOEWI
From Sandoz, AG and Felix-Platter Spital, Basle, Switzerland, and the M.R.C. Rheumatism Unit, Canadian Red Cross Memorial Hospital, Taplow, Maidenhead, Berks.

This paper reports the incidence of chemotactic activity of joint effusions obtained from several diseases involving joints. Ward and Zvaifler (1971) found that such activity was present in the majority of effusions in rheumatoid arthritis, but also in some cases of other nonspecified forms of inflammatory arthritis, gout, and osteoarthritis. These authors used rabbit neutrophil polymorphs to assess chemotaxis. We have repeated their observations using human polymorphs from both autologous and homologous sources. This work was conducted independently in two centres, using different methods. The results, which proved to be similar, are reported separately below.

Methods

Joint effusions were obtained from patients as detailed in Tables I and II. Diagnosis of rheumatoid arthritis (RA) was made in accordance with A.R.A. criteria, and of juvenile rheumatoid arthritis following the criteria of Ansell and Bywaters (1959). Other diseases were diagnosed according to the usually accepted criteria. Fluids were mixed with 15 units heparin/ml. No hyaluronidase was used for the Basle cases; it was used in a few of the Taplow cases, when the viscosity of fluids was high. The fluids were centrifuged at 1,800 g for 20 mins, to obtain clear supernatants. Some fluids were used fresh, others after storage at -20°C. Tests were conducted with joint fluids undiluted, or diluted 1:1 with Gey's medium.

White blood cells, the source of polymorphs, were obtained from heparinized (10 units/ml) human venous blood. Sedimentation was achieved by adding 1 ml dextran 110 (Fisons) to 10 ml blood, and sedimenting for 1 hour at room temperature. For the Taplow work, Plasmagel (Roger Bellon) was used instead. After centrifugation and washing in Gey's medium, the cells were suspended in Gey's containing 2% human serum albumin to give a leucocyte suspension of 1-1.5 x 10⁶ polymorphs/ml. For the method used at Taplow, a concentration of 3-4 x 10⁶/ml was used.

CHEMOTAXIS

This was assayed by a modified Boyden chamber technique (by J. F. B. and B. S.) (Boyden, 1962; Keller, Borel, Wilkinson, Hess, and Cottier, 1972) and by the method of Maroni, Symon, and Wilkinson (1972) (by G. L.). For the Boyden chamber technique, double filters were used.

Positive controls were supplied by the use of supernatant phase from a 24-hour culture of *Esch. coli*, diluted 1:10 in Gey's medium. Negative controls were Gey's containing 2% human serum albumin. Millipore filters of 3 µm pore size were used. The number of cells having completely moved to the lower aspect of the first filter during 2-5 hrs and the number of cells collected on the second filter (pore size 0.45 µm) were assessed and added. Rabbit neutrophils were obtained from peritoneal exudates, induced by casein injection.

The technique used by G. L. employed plastic tuberculin syringes the lower cut ends of which were sealed with millipore filters of 3 µm pore size. A suspension of white blood cells. Volume 0.2 ml, was placed above the filter, and the lower end was inserted into a 10 ml beaker containing joint fluid, a positive control, or a negative control. Three syringes were inserted into each beaker, affording observations in triplicate. For positive controls, normal human serum was activated by *Esch. coli endotoxin* (*Esch. coli* lipopolysaccharide B from *Esch. coli* 0127:B8) and subsequently inactivated by heating at 56° for 30 mins. The negative control, as in the other system, was Gey's medium, containing 2% human serum albumin. Chemotaxis was allowed to proceed for 2 hrs at 37°.

In Tables I and II fluids considered to have given a positive test are designated.

Results and discussion

These are tabulated separately for the Basle (J. F. B. and B. S.) and Taplow (G. L.) series. In the former, 20 out of 25 fluids tested induced polymorph chemotaxis. This was irrespective of diagnostic categories comprising rheumatoid arthritis, osteoarthritis, or Reiter's disease, and of the presence or absence of serum rheumatoid factor. In the Taplow series, 7 fluids of 18 tested induced chemotaxis. It was evident here also that the result was independent of the nature of the disease associated with the effusion. Ward and Zvaifler (1971), using a system with filters of 0.65 µm pore size, reported chemotaxis by fluids from cases of rheumatoid arthritis, inflammatory nonrheumatoid arthritis, gout, and osteoarthritis. It is evident that chemotactic activity remained in spite of the exhibition of various drugs. This does not, of course, imply that these regimens failed to affect the degree of chemotaxis in vivo. Direct addition in vitro of similar

Accepted for publication March 12, 1974.
### Table I  Chemotactic activity of synovial fluids assessed with autologous (A) or homologous (H) polymorphonuclear leucocytes, using the Boyden chamber technique

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Chemotactic assay with human PMN cells*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Controls (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>RA sero −</td>
<td>Phenylbutazone; gold</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>RA sero −</td>
<td>Phenylbutazone; gold</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>RA sero −</td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>RA sero −</td>
<td>D-penicillamine</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>RA sero +</td>
<td>Ibuprofen; gold; phenylbutazone; steroid</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>RA sero +</td>
<td>Ibuprofen; gold</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>RA sero +</td>
<td>Ibuprofen; steroid; phenylbutazone</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>RA sero +</td>
<td>Yttrium⁹⁰ D-penicillamine</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>RA sero +</td>
<td>Yttrium⁹⁰ D-penicillamine</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>Osteoarthritis</td>
<td>Phenylbutazone</td>
<td>0</td>
</tr>
<tr>
<td>11</td>
<td>Osteoarthritis</td>
<td>Indomethacin; nil for 7 days before aspiration</td>
<td>3</td>
</tr>
<tr>
<td>12</td>
<td>Osteoarthritis</td>
<td>Indomethacin; nil for 7 days before aspiration</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>Reiter's disease</td>
<td>Phenylbutazone</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>Reiter's disease</td>
<td>Phenylbutazone</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>Reiter's disease</td>
<td>Phenylbutazone</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>Reiter's disease</td>
<td>Phenylbutazone</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>Reiter's disease</td>
<td>Phenylbutazone</td>
<td>0</td>
</tr>
</tbody>
</table>

* Figures in the 3 columns denote average number of cells counted per high-power microscopical field. Controls (1): Gey's solution 2% HSA; Controls (2): supernatants from Esch. coli culture, 10% dilution in Gey's solution; synovial fluids: used undiluted.
† Culture supernatant diluted 20×, resulting in low value.
‡ Positive test.
NT: not tested.
Rheumatoid factor (sero +, sero −) was measured by latex test.

### Table II  Chemotactic activity of synovial fluids, assessed with homologous polymorphonuclear leucocytes, using a micromethod

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Chemotaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>18</td>
<td>RA sero −</td>
<td>Salicylate</td>
<td>10</td>
</tr>
<tr>
<td>19</td>
<td>RA sero +</td>
<td>Salicylate</td>
<td>21</td>
</tr>
<tr>
<td>20</td>
<td>RA sero +</td>
<td>Salicylate; phenylbutazone</td>
<td>13</td>
</tr>
<tr>
<td>21</td>
<td>RA sero +</td>
<td>Salicylate; indomethacin</td>
<td>5</td>
</tr>
<tr>
<td>22</td>
<td>RA sero −</td>
<td>Ibuprofen</td>
<td>21</td>
</tr>
<tr>
<td>23</td>
<td>RA sero −</td>
<td>Salicylate</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>RA sero −</td>
<td>Salicylate</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>RA sero +</td>
<td>Salicylate</td>
<td>21</td>
</tr>
<tr>
<td>26</td>
<td>RA sero −</td>
<td>Salicylate</td>
<td>12</td>
</tr>
<tr>
<td>27</td>
<td>RA sero +</td>
<td>Gold</td>
<td>27</td>
</tr>
<tr>
<td>28</td>
<td>RA sero −</td>
<td>Salicylate</td>
<td>17</td>
</tr>
<tr>
<td>29</td>
<td>RA infectious arthrodesis sero −</td>
<td>Salicylate; indomethacin</td>
<td>13</td>
</tr>
<tr>
<td>30</td>
<td>Intermittent hydrarthrosis sero −</td>
<td>Salicylate; indomethacin</td>
<td>5</td>
</tr>
<tr>
<td>31</td>
<td>Osteoarthritis sero −</td>
<td>Salicylate; indomethacin</td>
<td>4</td>
</tr>
</tbody>
</table>

* Controls: Endotoxin-activated human serum.
† Positive test.
For other explanatory notes, see Table I.
drugs to chemotactic systems has been shown not to affect the migratory behaviour of polymorphs (Borel, 1973). Table I shows that both homologous and autologous polymorphs can respond to joint fluid by chemotaxis. This result was not unexpected, but it shows that polymorphs from seropositive rheumatoid patients are able to migrate to an inflammatory focus. Mowat and Baum (1971) showed that cells from rheumatoid patients responded to a chemotactic stimulus to a lesser degree than the cells of normal controls. Their results suggested that this might be caused by the in vivo uptake of complexes by these cells. In a few experiments we have used the cells from joint exudates as the migratory test population using Esch. coli supernatant as stimulus. The cells behaved normally; the prevalence of immune complex inclusions within cells of an inflammatory joint exudate has been extensively documented (Hollander, McCarty, Astorga, and Castro-Murillo, 1965).

The results we report were obtained with human polymorphs. Others (Ward and Zvaifler, 1971) have employed rabbit cells. In preliminary experiments of our own, using rabbit polymorphonuclear cells, we obtained inconsistent results. Undiluted synovial fluids, which had proved strongly chemotactic for human cells, induced chemotaxis in cells of some rabbits while they were inactive for the cells of some other rabbits. The results were also inconsistent between individual experiments. The situation was further complicated by the finding that progressive dilution of joint fluid in some cases led to increased rabbit-cell migration, which was never found with human cells.

The nature of chemotactic factors in joint fluid has been investigated by Ward and Zvaifler (1971). They have adduced evidence for the presence of the complement-derived factor C5a and the cleavage product C5b as mediators of activity in rheumatoid effusions, while nonrheumatoid fluids contained a chemotactic factor (C3a) derived from C3. In an earlier paper (Zvaifler, 1969), a fast-moving breakdown product of C3 had, however, been found to be correlated with rheumatoid arthritis and the presence of rheumatoid factor. Both Borel, Sorkin, and Loewi (1971) and Wagner, Abraham, and Baum (1972) have shown that rheumatoid factor can cause the generation of chemotaxis in the presence of serum. This might, therefore, provide a positive mechanism in some joint fluids, via a complement sequence.

**Summary**

Joint fluids from patients with several diseases associated with arthritis were tested for polymorph chemotaxis. A high proportion was found to be positive, using two different systems in two centres. No relationship to serum rheumatoid factor, type of disease, or drug therapy was indicated by the findings.

We thank the physicians at the M.R.C. Rheumatism Unit and at Northwick Park Hospital, Harrow, for the provision of samples of joint fluids.

**References**


———, Sorkin, E., and Loewi, G. (1971) Immunology, 21, 165 (Neutrophil chemotaxis mediated by rheumatoid factor)


Zvaifler, N. J. (1969) Ibid., 48, 1532 (Breakdown products of C3 in human synovial fluids)
Chemotactic effect of joint effusions.

B Stojan, J F Borel and G Loewi

Ann Rheum Dis 1974 33: 425-427
doi: 10.1136/ard.33.5.425

Updated information and services can be found at:
http://ard.bmj.com/content/33/5/425.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/